MMP9 and MMP2 Substrate (Fluorogenic) – PEPDAB011

Specifications and Use

Fluorescent Substrate: Dabcyl-GPLGMRGK(FAM)-NH2

Catalog Number:          PEPDAB011m001, 1mg, 125 USD

Catalog Number:          PEPDAB011m005, 5mg, 500 USD

Proceed to Checkout

Substrate Specificities PEPDAB011


This mmp substrate can be used to assess activity of MMP9 and MMP2. This mmp substrate has been used in enzymatic and cell based assays to assess activity of MMP9 and MMP2 since it is specific for this family of metalloproteinases. See our Product Sheets for its substrate specificity profile. Typically, the peptide is dissolved in DMSO to make a stock solution of about 10uM concentration. When used for in vitro assays, the substrate is often used at about 10mM concentration. Remember to keep the DMSO concentration in the final reaction at 1% or below, to avoid DMSO effects on the reaction, and remember to have an equivalent percentage of DMSO in the background wells. For use with the MMPs, the buffer should contain 50 mM Tris, pH 7.5, 150 mM NaCl, 2 mM CaCl2, 5 µM ZnSO4, and 0.01% Brij-35. Excitation and emission wavelengths are 485 and 530 nm respectively.

Molecular Weight:

1423.4 g/mol


Greater than 95% as assessed by HPLC and Mass Spectrometry.


1 mg/ml in water with 10% Formic acid


Red lyophilized powder


The peptide powder is shipped at room temperature.


Upon receiving, the peptide should be stored at -70 oC. Avoid repeated freeze-thaw cycles. If dissolved in liquid (such as DMSO), aliquot into separate tubes to minimize the number of freeze-thaw cycles.


Samples are sensitive to light and stable up to 6 months at -70oC.


1. Use of a multiple-enzyme/multiple-reagent assay system to quantify activity levels in samples containing mixtures of matrix metalloproteinases. Rasmussen FH, Yeung N, Kiefer L, Murphy G, Lopez-Otin C, Vitek MP, Moss ML. Biochemistry 2004 Mar 23;43(11):2987-95.

2.Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities. Miles A Miller, Layla Barkal, Karen Jeng, Andreas Herrlich, Marcia Moss, Linda G Griffith, Douglas A Lauffenburger Integrative Biology 12/2010; 3(4):422-38.

3.Potential of Fluorescent Metalloproteinase Substrates for Cancer Detection. Roopali Roy,1,5 David Zurakowski,2,5 Susan Pories,3 Marcia L. Moss,4,* and Marsha A. Moses1,5Clin Biochem. 2011 December; 44(17-18): 1434–1439.

4.Low-volume multiplexed proteolytic activity assay and inhibitor analysis through a pico-injector array. Ee Xien Ng, Miles A. Miller, Tengyang Jing,  Doug A. Lauffenburger and   Chia-Hung Chen,   Lab Chip, 2015,15, 1153-1159. DOI: 10.1039/C4LC01162G

5.ADAM8 as a drug target in pancreatic cancer. Uwe Schlomann, Garrit Koller, Catharina Conrad, Taheera Ferdous, Panagiota Golfi, Adolfo Molejon Garcia, Sabrina Höfling, Maddy Parsons, Patricia Costa, Robin Soper, Maud Bossard, Thorsten Hagemann, Rozita Roshani, Norbert Sewald, Randal R. Ketchem, Marcia L. Moss, Fred H. Rasmussen, Miles A. Miller, Douglas A. Lauffenburger, David A. Tuveson, Christopher Nimsky & Jörg W. Bartsch Nature Communications, 6,Article number: 6175, doi:10.1038/ncomms7175